Research Analysts’ Price Target Changes for December, 9th (AGIO, AMGN, ATVI, BF/B, BMY, CHK, CLDR, CRWD, FATE, FIVN)

Research Analysts’ price target changes for Monday, December 9th:

Agios Pharmaceuticals (NASDAQ:AGIO) had its target price boosted by BMO Capital Markets to $49.00. BMO Capital Markets currently has an outperform rating on the stock.

Amgen (NASDAQ:AMGN) had its price target raised by Argus to $265.00. Argus currently has a buy rating on the stock.

Activision Blizzard (NASDAQ:ATVI) had its target price raised by SunTrust Banks, Inc. to $61.00. They currently have a positive rating on the stock.

Brown-Forman (NASDAQ:BF/B) had its target price increased by Citigroup Inc from $67.00 to $68.00. They currently have a neutral rating on the stock.

Brown-Forman (NASDAQ:BF/B) had its target price increased by Morgan Stanley from $56.00 to $60.00. They currently have an equal weight rating on the stock.

Bristol-Myers Squibb (NYSE:BMY) had its price target boosted by Mizuho from $3.14 to $3.99.

Chesapeake Energy (NYSE:CHK) had its target price trimmed by Imperial Capital to $2.00. The firm currently has an in-line rating on the stock.

Cloudera (NYSE:CLDR) had its target price raised by Citigroup Inc from $8.00 to $10.00. The firm currently has a neutral rating on the stock.

Crowdstrike (NASDAQ:CRWD) had its target price boosted by Nomura from $65.00 to $71.00. The firm currently has a buy rating on the stock.

Fate Therapeutics (NASDAQ:FATE) had its target price lowered by BMO Capital Markets to $22.00. The firm currently has an outperform rating on the stock.

Five9 (NASDAQ:FIVN) had its price target increased by Guggenheim from $70.00 to $80.00. Guggenheim currently has a buy rating on the stock.

Guidewire Software (NYSE:GWRE) had its price target raised by Citigroup Inc from $97.00 to $115.00. The firm currently has a neutral rating on the stock.

Kite Realty Group Trust (NYSE:KRG) had its target price raised by Citigroup Inc from $16.00 to $19.50. Citigroup Inc currently has a neutral rating on the stock.

Lanxess (ETR:LXS) was given a €73.00 ($84.88) target price by analysts at Deutsche Bank AG. The firm currently has a buy rating on the stock.

Oracle (NYSE:ORCL) was given a $62.00 price target by analysts at Goldman Sachs Group Inc. The firm currently has a buy rating on the stock.

Rocket Pharmaceuticals (NASDAQ:RCKT) had its target price increased by Oppenheimer Holdings Inc. from $36.00 to $42.00. They currently have an outperform rating on the stock.

Rheinmetall (ETR:RHM) was given a €110.00 ($127.91) price target by analysts at HSBC Holdings plc. The firm currently has a neutral rating on the stock.

Renasant (NASDAQ:RNST) had its target price boosted by Stephens from $34.00 to $38.00. Stephens currently has an equal weight rating on the stock.

Spirit Realty Capital (NYSE:SRC) had its target price boosted by Morgan Stanley from $51.00 to $56.00. Morgan Stanley currently has an overweight rating on the stock.

UniCredit (BIT:UCG) was given a €17.50 ($20.35) target price by analysts at Goldman Sachs Group Inc. The firm currently has a buy rating on the stock.

Receive News & Ratings for Agios Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.